Market Cap: $643.31M
CI
CorMedix Inc.
CRMD
NASDAQ (NASDAQ Global Market)USD
Market Cap: $643.31M
### CorMedix Champions Innovation and Growth in Q4 Earnings CorMedix (NASDAQ: CRMD) unveils its Q4 earnings with a focus on transformative advancements in its product pipeline, aligning with the compa…
Cormedix Charts a Promising Path Ahead with Q4 Earnings Announcement As Cormedix (NASDAQ: CRMD) gears up for its quarterly earnings release on March 5, 2026, it stands at a crucial intersection betwee…
Cormedix's Q4 Earnings Highlight Promising Developments in Product Pipeline Cormedix (NASDAQ: CRMD) prepares to release its quarterly earnings report on March 5, 2026, a significant event that promise…
CorMedix Faces Scrutiny Amid Insider Sale by Director In a recent development, CorMedix, a biopharmaceutical company specializing in therapeutic products for cardiovascular and infectious diseases, dr…
CorMedix Faces Scrutiny Following Insider Sale CorMedix, a biopharmaceutical company focused on developing therapeutic products for cardiovascular and infectious diseases, finds itself under scrutiny…
CorMedix Faces Scrutiny Following Insider Sale CorMedix, a biopharmaceutical company focused on developing therapeutic products for cardiovascular and infectious diseases, experiences heightened scrut…
Confidence in Innovation: Janet Dillione’s Strategic Move at CorMedix In a significant development for CorMedix, Janet Dillione, the company's Director, exercises a substantial number of stock options…
Janet Dillione's Bold Move: A Vote of Confidence in CorMedix's Future In a significant development for CorMedix, Janet Dillione, the company's Director, exercises a substantial number of stock options…
Cormedix Director's Strategic Move Reflects Confidence in Healthcare Innovation Janet Dillione, Director at CorMedix, recently exercises a substantial number of stock options, a move that underscores…
CorMedix Faces Scrutiny Following Insider Sale by Director In a recent SEC filing, CorMedix Director Janet Dillione has executed an insider sell, raising eyebrows in the biotech community. Although th…
CorMedix Faces Scrutiny Over Insider Trading Activity CorMedix, a biotechnology company dedicated to developing therapeutics and diagnostic products for infectious diseases and cardiovascular conditio…
Insider Transactions: A Window into Cormedix's Leadership Dynamics In the biotech sector, transparency and executive actions play a pivotal role in shaping investor sentiment. Recently, Janet Dillione…
CorMedix Reports Strong Earnings, Highlighting Growth in Kidney Health Sector CorMedix Inc. (NASDAQ:CRMD) announces its third-quarter earnings, showcasing a remarkable profit of $1.26 per share, far e…
CorMedix Reports Strong Third-Quarter Earnings, Exceeding Expectations CorMedix Inc. (NASDAQ: CRMD) announces a strong financial performance for the third quarter, reporting earnings of $1.26 per shar…
CorMedix Surpasses Earnings Expectations, Signaling Strong Market Position CorMedix Inc. (NASDAQ: CRMD) presents an encouraging outlook following its third-quarter earnings announcement, revealing a p…
Insider Confidence: Myron Kaplan's Strategic Move at CorMedix On October 28, 2023, Myron Kaplan, a board member at CorMedix, makes a strategic insider purchase, signaling strong confidence in the comp…
Confidence in CorMedix: Insider Purchase Signals Positive Outlook On October 28, 2023, Myron Kaplan, a Board Member of CorMedix, makes a notable insider purchase, as documented in a recent SEC filing.…
Strategic Collaboration: CorMedix Strengthens Ties with Talphera CorMedix Inc. forges a pivotal relationship with Talphera, Inc. by appointing its CEO, Joe Todisco, to Talphera's Board of Directors. T…
Strategic Collaboration Enhances Talphera’s Growth Potential in Anticoagulation Therapy Talphera, Inc., a specialty pharmaceutical firm focused on developing innovative therapies, appoints Joe Todisco…
Insider Confidence: A Strategic Move for CorMedix's Future On September 19, 2023, Duncan, a director at CorMedix, engages in a significant transaction by exercising stock options, signaling a strong v…
Insider Activity Signals Confidence at CorMedix Recent insider transactions at CorMedix (CRMD) draw attention to the company's leadership and its potential impact on investor sentiment. On September 1…
CorMedix Navigates Insider Trading Dynamics Amidst Market Scrutiny CorMedix (CRMD) finds itself in the spotlight following a notable insider transaction on September 17, when Director Dunton executed…
CorMedix Insider Activity Signals Potential Strategic Shifts Recent insider trading activity at CorMedix (CRMD) raises questions regarding the company's strategic direction as Director Dunton exercise…
Cormedix Executive Takes Bold Step to Reinforce Company Commitment Cormedix, a biotech firm focusing on innovative therapies for renal and cardiovascular health, garners attention following a signific…
CorMedix Leadership Takes Strategic Steps in Healthcare Innovation CorMedix, a biopharmaceutical company focused on developing innovative therapies for renal and cardiovascular health, garners attenti…